Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Depression may not be causally linked to prostate cancer risk

Key clinical point: This Mendelian randomization (MR) study found no clear evidence to support the causal role of genetically predicted depression on the risk of prostate cancer.

Major finding: No evidence was found for a potential causal effect of major depressive disorder (MDD) on the risk of prostate cancer in inverse‐variance weighted (odds ratio [OR], 1.12; P = .135), MR‐Egger (OR, 0.89; P = .833), and weighted median (OR, 1.08; P = .350). The result of inverse‐variance weighted showed that depressive status had no causality on prostate cancer (OR, 0.72; P = .364).

Study details: Two-sample MR analysis, using 44 single-nucleotide polymorphisms (SNPs) associated with MDD and 2 SNPs related to depressive status as ever depressed for a whole week, evaluated the causal effect of depression on the risk of prostate cancer.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.


Chen X et al. Cancer Med. 2020 Oct 7. doi: 10.1002/cam4.3493.